AANP Family Nurse Practitioner (FNP) Certification ExamEvaluationHard
A 60-year-old male with Type 2 Diabetes Mellitus and obesity (BMI 32 kg/m²) is on metformin 1000 mg BID. His A1C is 7.8%, and he has established atherosclerotic cardiovascular disease (ASCVD). What is the most appropriate addition to his current regimen to improve glycemic control and reduce cardiovascular risk?
- AAdd empagliflozin.
- BAdd pioglitazone.
- CAdd glipizide.
- DAdd insulin glargine.
Show answer & explanationAnswer & explanation
Correct answer: A. Add empagliflozin.
For patients with Type 2 Diabetes and established ASCVD, current guidelines recommend adding an SGLT2 inhibitor (like empagliflozin) or a GLP-1 receptor agonist with proven cardiovascular benefits, irrespective of A1C target, to reduce cardiovascular events.
Why the other options are wrong
- B. Pioglitazone (a thiazolidinedione) can improve glycemic control but is associated with weight gain and increased risk of heart failure, which is undesirable in a patient with ASCVD and obesity.
- C. Glipizide (a sulfonylurea) improves glycemic control but lacks cardiovascular benefit and carries a risk of hypoglycemia and weight gain, making it a less preferred option in this patient.
- D. Insulin glargine improves glycemic control but does not provide the specific cardiovascular risk reduction benefits seen with SGLT2 inhibitors or GLP-1 RAs in patients with ASCVD.
T2DM with ASCVD Management
In patients with Type 2 Diabetes and established atherosclerotic cardiovascular disease (ASCVD), an SGLT2 inhibitor or a GLP-1 receptor agonist with proven cardiovascular benefit should be added to metformin, regardless of A1C.
- Prioritize agents with CV benefits in high-risk patients.
- SGLT2 inhibitors (e.g., empagliflozin, canagliflozin) reduce MACE and HF hospitalization.
- GLP-1 RAs (e.g., liraglutide, semaglutide) reduce MACE.
Memory trick: When T2DM meets a struggling heart, choose the meds that play a protective part.